Kazuhiro Nouso

Okayama University — Japan

Medicine · Health Sciences

50h-index9.1kcitations415works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(214), Liver Disease Diagnosis and Treatment(158), Hepatitis C virus research(57), Cholangiocarcinoma and Gallbladder Cancer Studies(47), Pancreatic and Hepatic Oncology Research(44)

Publications413 total

Validation of Liquid Biopsy Using a Methylated <i>SEPT9</i> Assay and Integrated Index for Detecting Hepatocellular Carcinoma
Hepatology Research·2025
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
Hepatology Research·2025Open Access
Clinical Utility of a Prognostic Scoring System Based on <scp>LDH</scp> and <scp>CRP</scp> in <scp>HCC</scp> Patients Receiving Atezolizumab Plus Bevacizumab
Liver International·2025
Usefulness of the Fibrosis-3 index in patients with hepatitis C
Annals of Medicine and Surgery·2025Open Access
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis
Hepatology Research·2025
Definition of Conversion Therapy in Patients with Hepatocellular Carcinoma
Kanzo·2025· 1 citedOpen Access
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma
Hepatology Communications·2025· 1 citedOpen Access
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma
Journal of Gastroenterology·2025· 1 cited
Effectiveness of screening and ultra-brief intervention for hazardous drinking in primary care: pragmatic cluster randomised controlled trial
BMJ·2025· 2 citedOpen Access
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma
Oncology·2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
Hepatology Research·2025· 1 cited
Efficacy and safety of a digital therapeutic for alcohol dependence: A multicenter, open‐label, randomized controlled trial
Psychiatry and Clinical Neurosciences·2025· 1 citedOpen Access
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma
Liver Cancer·2025Open Access
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab
Liver International·2025· 2 cited
Clinical Impact of Serum <scp>CRP</scp> Levels on Advanced <scp>HCC</scp> Treated With Durvalumab and Tremelimumab: A Multicentre Study
Liver International·2025· 5 cited
Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
Hepatology Research·2025· 3 cited
Comparison of Surgical Resection and Radiofrequency Ablation for Early‐Stage HCC Patients With Child–Pugh Class B
Journal of Gastroenterology and Hepatology·2025· 3 cited
Association Between Initial Symptoms and Clinical Outcomes in COVID-19
Cureus·2025Open Access
Utility of the fibrosis-3 index for predicting liver fibrosis 5 years after achieving sustained virological response in patients with chronic hepatitis C
Clinics and Research in Hepatology and Gastroenterology·2025· 1 cited
Site-Specific <i>O</i>-Glycosylation in Oncofetal Fibronectin IIICS Domain Creates Cancer Stage-Specific Biomarkers
Journal of the American Chemical Society·2025· 2 cited
page 1 of 21Next →

Frequent Co-authors

Kazuya Kariyama(21), Atsushi Hiraoka(18), Shinichiro Nakamura(18), Takashi Kumada(17), Ei Itobayashi(17), Toru Ishikawa(17), Toshifumi Tada(17), Hidenori Toyoda(17), Kunihiko Tsuji(16), Koichi Takaguchi(16), Masashi Hirooka(16), Yoichi Hiasa(16), Hironori Ochi(15), Kazuto Tajiri(15), Kouji Joko(15), Akemi Tsutsui(15), Noritomo Shimada(13), Masanori Atsukawa(12), Norio Itokawa(12), Michitaka Imai(12)